The Venture Codex

Led · Series C · May 2022

OncoHost develops PROphet®, a machine learning-based host response profiling platform that analyzes proteomic changes in blood samples to monitor patients' biological response to cancer therapies. The company combines life-science research and advanced machine learning to design personalized strategies aimed at overcoming therapy resistance. Led by CEO Dr. Ofer Sharon and based in Binyamina, Israel, OncoHost uses proprietary proteomic analysis to understand individual patient responses. It is expanding clinical trial sites worldwide and broadening research into additional cancer indications. PROphet® is planned for U.S. commercial launch in the third quarter of 2022. The company recently completed a financing that will fund its multicenter PROPHETIC trial and support the imminent U.S. launch. OncoHost is a clinical-stage precision oncology startup based in Binyamina, Israel, combining life-science research with advanced machine learning to develop personalized cancer-treatment strategies. Its core product, PROphet®, is a machine learning–based Host Response Profiling platform that combines proteomic analysis with AI to predict patient response to immunotherapy and suggest combination strategies to overcome resistance. The company analyzes proteomic changes in patient blood samples to detect signs of resistance in real time, enabling biomarker-guided treatment planning and target discovery for drug development. Clinical trials are underway in melanoma and non-small cell lung cancer (NSCLC) patients, with plans to expand to other indications. The company is led by CEO Ofer Sharon, MD. The recently completed financing will support ongoing clinical trials, opening a U.S.-based affiliate, and preparation for the commercial launch of PROphet® to healthcare providers.

Participated · Series D · Nov 2021

SafeBreach provides a patented continuous security validation platform that automatically and safely executes thousands of attack methods to validate network, endpoint, cloud, container and email security controls against its Hacker’s Playbook. The platform is used to simulate attacks broken down by methods, tactics and threat actors to assess security posture. SafeBreach protects nearly 100 enterprise customers, all within the Fortune 1000, including the top five largest financial, healthcare and pharmaceutical companies involved in COVID-19 vaccine and remediation efforts. Led by co-founder and CEO Guy Bejerano, the company is positioned as a leader in the BAS market. SafeBreach says it will use the new funding to accelerate geographic expansion and to evolve its product offerings. The company has now raised more than $106 million in total funding. SafeBreach offers a patented breach-and-attack simulation (BAS) platform that executes thousands of breach methods to validate network, endpoint, cloud and email security controls using a Hacker’s Playbook™ of research and real-world data. The platform gives a near real-time “hacker’s view” of an enterprise’s security posture to proactively predict attacks and improve SOC analyst response capabilities. Customers include dozens of multi-billion-dollar organizations across financial services, healthcare, manufacturing, telecommunications and retail. The company is led by co-founder and CEO Guy Bejerano and is based in Sunnyvale, California. SafeBreach plans to use new funding to accelerate product development, expand sales channels and partnerships globally, and add a suite of new services. SafeBreach offers a Breach and Attack Simulation platform that automatically executes thousands of breach methods from a growing Hacker’s Playbook to predict attacks, validate security controls and improve SOC analyst response. The platform provides a “hacker’s view” of an enterprise’s security posture to proactively identify weaknesses. Led by CEO and co-founder Guy Bejerano, the company emphasizes research and real-world investigative data in its simulation library. SafeBreach intends to use newly raised funds to continue expanding operations. The article reports a strategic funding round of $15M, indicating recent capital support to fuel growth. SafeBreach is a Sunnyvale, CA-based provider of a continuous security validation platform. Its platform provides a “hacker’s view” of an enterprise’s security posture to proactively predict attacks, validate security controls and improve SOC analyst response. The solution automatically executes breach methods using an extensive Hacker’s Playbook™ of research and real-world investigative data. Customers include financial, high-tech and retail companies deploying the platform to test the efficacy of security controls, validate compliance and identify outbound exfiltration routes. The company closed a $15M Series A in July 2016 and intends to use the funds to expand research and development as well as sales and marketing headcount. SafeBreach is led by CEO Guy Bejerano, CTO Itzik Kotler and VP of Security Research Amit Klein.

Participated · Series A · Apr 2021

LocusView Solutions Inc. announced a $64 million Series A round on April 28, 2021. The round was led by Israel Growth Partners, a new investor in the company. Other participants included new investors Clal Insurance Enterprises Holdings Ltd. (TASE:CLIS), Discount Capital, and Leumi Partners Ltd., alongside existing investors. The reporting describes the financing specifically as a Series A round. The company has raised $80 million in total funding to date.

Participated · Series B · Mar 2021

Seebo provides a Process-Based Artificial Intelligence solution that enables manufacturers to identify process-driven inefficiencies in their production processes in order to predict and prevent production losses. The company's offering focuses on predictive quality and yield for manufacturing operations. Customers include leading manufacturers such as Nestle, PepsiCo, General Mills, Barilla, Mondelez, Allnex and ICL. Seebo is led by CEO and co-founder Lior Akavia. The company said it will use the funding to further expand its global reach and continue enhancing its solution. Seebo is based in Tel Aviv, Israel. Seebo provides a cloud-based software platform that combines IoT modeling, simulation and execution tools to quickly turn existing machinery into smart, connected systems that report health and usage data. Behavioral analytics are automatically layered on top of this big data to provide insights that drive ongoing product improvement and new business value. The platform targets industrial IoT use cases including product resilience, production efficiency and data-driven product innovation, and serves manufacturers across dozens of industries, including Multotec, Oseco, Durabrite and Stanley Tools. Founded in 2012, Seebo has offices in Tel Aviv, San Francisco and Shenzhen. Over the last six months the company enhanced its offering with IoT Simulation and Behavior Analytics to power data-driven services and user insight. It plans to use the new funds to support growth of its IIoT platform and extend strategic partnerships. As of this extension Seebo has raised $22M in total funding, with the Series A round totaling $16.5M.

Participated · Series C · Feb 2021

Medisafe builds medication-management digital drug companions and deploys AI-driven personalization (JITI™) to support patients across their therapy journeys. The platform has over 7M registered users and a database of more than four billion dosage behaviors that inform its Just-in-Time-Interventions engine. Medisafe partners with global pharma companies and is expanding opportunities across the broader health ecosystem. Product offerings include Medisafe Care Connector, launched in 2020 to link clinicians into patient support programs, and Maestro, a proprietary no-code technology for building and optimizing personalized journeys introduced last September. The company is led by CEO Omri Shor and was founded in 2012. It intends to use new funding to expand end-to-end solutions and accelerate revenue growth. Medisafe is a Boston-based personalized medication management platform that addresses major causes of medication non-adherence. Its cloud-based mobile platform personalizes content, resources and interventions, including educational videos, coupons and motivational messages, based on each user’s regimen, condition and circumstances. The platform runs on iOS and Android and has been used by over 3.5 million patient and caregiver registered users who have recorded over 500 million medication doses and contributed 140,000 app-store reviews. Led by CEO and co-founder Omri Shor, the company plans to use new funding to expand sales, marketing and engineering teams. Medisafe also intends to open a European office to support international growth. These moves are aimed at scaling operations and increasing adoption of its medication‑adherence tools. MediSafe is a mobile-first medication management platform that reminds patients to take medications and alerts caregivers when doses are missed. The company delivers personalized interventions addressing forgetfulness, lack of support, emotional distress, information overload, low engagement, and medication cost barriers. Its platform enables tighter care coordination between patients, “MedFriends” (caregivers), physicians, and other providers. MediSafe reports more than 1.3 million downloads across iOS and Android and about 52,000 ratings averaging 4.5 out of 5. The company has won multiple industry awards and recognition for its mHealth solution. MediSafe plans to expand its suite of medication-management solutions, enhance user experience in its apps, accelerate U.S. user growth, and pursue distribution, technology, and data partnerships as part of its market expansion. MediSafe provides a cloud-synced mobile medication management app that reminds patients when to take medications and sends alerts to caretakers if doses are missed. The platform anonymously aggregates de-identified, self-reported user data and reports an 86% adherence rate among its users. MediSafe plans to use recent funding to build partnership programs with pharmaceutical companies, pharmacies, HMOs, employers and hospitals to better manage medication adherence. The company positions its analytics to give healthcare leaders insight into patient behavior and the issue of non-adherence. MediSafe was co-founded in mid 2012, graduated from the Microsoft Ventures Accelerator, and has seen growth in user adoption and satisfaction. The $1 million funding is intended to support product enhancements, partnership development, and continued expansion of its analytics capabilities.